Somewhat Positive News Coverage Somewhat Unlikely to Affect Aquinox Pharmaceuticals (AQXP) Share Price
News stories about Aquinox Pharmaceuticals (NASDAQ:AQXP) have been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aquinox Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.0191710256217 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
A number of brokerages have weighed in on AQXP. Canaccord Genuity restated a “buy” rating and issued a $22.00 target price on shares of Aquinox Pharmaceuticals in a research report on Tuesday, November 21st. Cantor Fitzgerald restated a “buy” rating and issued a $28.00 target price on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Needham & Company LLC restated a “buy” rating and issued a $25.00 target price on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Finally, ValuEngine lowered shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $22.50.
Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) opened at $11.62 on Friday. Aquinox Pharmaceuticals has a 52-week low of $10.02 and a 52-week high of $19.97. The firm has a market cap of $277.36, a P/E ratio of -6.02 and a beta of -16.96.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.